Table 21Characteristics of exenatide active-control trials in adults with type 2 diabetes

Author, year
Quality
Sample size (N)
Follow- up (weeks)
Age (years) (SD)a
% Malea
% Whitea
% Hispanica
Diabetes duration (years)a
Baseline HbA1c (%) (SD)a
Weight (kg)a
BMI (kg/m2)a
InterventionCombination therapy
Barnett 200762
Fair
138
16
54.4–55.3 (1.1–1.2)
45.7 – 48.5
NR
6.6–8.3 (0.6–0.7)
8.89 (0.13)
84.0–85.6(2.0)
30.9–31.3 (0.5)
Exenatide: 10 mcg BID
Insulin glargine
Both groups continued prior MET or SU
Davis, 200765
Fair
51
16
52–54 (8)
56–50
NR
NR
10–12 (6–7)
8.0–8.3 (0.9–1.2)
95–102 (17–19)
33–35 (4)
Exenatide: 10 mcg BID
Insulin: various
Both groups received MET +/− SU or SU
Heine, 200563
Boye, 2006
Fair
551
26
58–59.8 (8.8–9.5)
55–56.6
79.8–80.5
15–15.6
9.2–9.9 (5.7–6.0)
8.2–8.3(–1.0)
87.5–88.3 (16.9 –17.9)
31.3–31.4 (4.4–4.6)
Exenatide: 10 mcg BID
Insulin glargine
Both groups received maximum
MET and SU
Nauck, 200764
Fair
505
52
58–59 (9)
49–53
NR
NR
9.8–10.0 (6.2–6.3)
8.6 (1.0–1.1)
83.4–85.5 (15.6–15.7)
30.4 (4.1)
Exenatide: 10 mcg BID
Biphasic insulin aspart
Both groups received MET and SU
DeFronzo, 201067
Fair
137
20
56 (10)
51
61
23
4.7 (3.7)
7.8 (0.7)
NR
32.5 (4.3)
Exenatide: 10 mcg BID
Rosiglitazone 4 mg BID
Exenatide and Rosiglitazone
All groups continued on prior MET
Derosa, 201066
Fair
128
52
56–57 (7–8)
48–50
NR
NR
NR
8.8–8.9 (0.7–0.8)
82.0–82.4 (8.3–9.1)
28.5–28.7 (1.4–1.5)
Exenatide: 10 mcg BID
Glibenclamide 5 mg TID
Both groups continued on prior MET

Abbreviations: BID, twice daily; TID, three times daily; BMI, body mass index; MET, metformin; NR, not reported; SD, standard deviation; SU, sulfonylurea.

a

Data presented are the range across treatment groups for mean and standard deviation.

From: Results

Cover of Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations
Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report [Internet].
Jonas D, Van Scoyoc E, Gerrald K, et al.
Portland (OR): Oregon Health & Science University; 2011 Feb.
Copyright © 2011, Oregon Health & Science University.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.